Regulatory and product development consulting firm
Total Trials
27
As Lead Sponsor
14
As Collaborator
13
Total Enrollment
12,288
NCT00002470
Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid Tumors
Phase: Phase 2
Role: Collaborator
Start: Sep 30, 1990
Completion: Jan 31, 2004
NCT00002504
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Start: Aug 31, 1992
Completion: Feb 28, 1999
NCT00002505
Tumor Cell Vaccine in Treating Patients With Advanced Cancer
Completion: May 31, 2006
NCT00002506
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer
NCT00003090
Biological Therapy in Previously Treated Patients With Non-small Cell Lung Cancer
Role: Lead Sponsor
Start: Jan 31, 1996
Completion: Not specified
NCT00003091
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
Completion: Jan 31, 2000
NCT00003604
Interleukin-2 in Treating Patients With Stage III or Stage IV Kidney Cancer That Has Been Removed With Surgery
Start: Oct 31, 1997
NCT00003605
Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma
Start: May 31, 1998
NCT00003663
Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma
Start: Jun 30, 1998
NCT00004039
Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
NCT00004040
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
Completion: Jun 30, 1999
NCT00003664
Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically
Start: Oct 31, 1998
NCT00049413
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
Start: Jun 30, 2002
Completion: Dec 31, 2005
NCT00564330
In Vivo Quantification of Dental Demineralisation Using OCT With and Without Esomeprazole
Phase: Phase 1/2
Start: Nov 30, 2007
Completion: May 31, 2008
NCT00964483
Translating Dietary Trials Into the Community
Phase: N/A
Start: Jan 31, 2010
Completion: Sep 30, 2010
NCT01705171
Is the Expression of the GLUT5 Specific Fructose Transport Protein Abnormal in Patients With Fructose Intolerance?
Start: Dec 31, 2011
Completion: Oct 31, 2013
NCT01511523
Study to Evaluate the Effect of RGMA001 on Patients With Non Alcoholic Fatty Liver Disease (NAFLD)
Start: Jan 31, 2012
Completion: Oct 31, 2012
NCT02362737
Active and Healthy Brotherhood: A Program for Chronic Disease Self-Management for Black Men
Start: Jan 31, 2015
Completion: Jun 30, 2018
NCT02614313
Fructose Breath-testing in Irritable Bowel Syndrome (IBS)
Start: Jun 30, 2016
Completion: Aug 31, 2017
NCT03204448
Clinical Performance of BioCLIA Ro60
Start: May 8, 2017
Completion: Apr 16, 2020
NCT02087345
Gastro-oesophageal Reflux in Oligosymptomatic Patients With Dental Erosion
Start: Dec 15, 2018
Completion: Jun 30, 2023
NCT04331223
The Association of Clinical Symptom Clusters With Underlying Mechanisms in Functional Gastrointestinal Disorders
Completion: Aug 31, 2019
NCT02085889
Fructose and Lactose Intolerance and Malabsorption in Functional Gastrointestinal Disorders
Start: Mar 1, 2019
Completion: Dec 31, 2022
NCT04824976
Effects of Blueberries on Symptoms and Underlying Mechanisms of Functional Gastrointestinal Disorders
Start: Jan 1, 2020
Completion: Apr 1, 2022
NCT05472402
Feasibility and Acceptability of an Online Program to Promote Physical Activity Among Black Women
Start: May 22, 2022
Completion: Nov 30, 2025
NCT06349863
Dutch Cholecystitis Snapshot Study
Start: Apr 1, 2024
Completion: Oct 30, 2025
NCT06854094
Consolidation Therapy with Cladribine in Relapsing Multiple Sclerosis Patients
Start: Oct 3, 2024
Completion: Dec 31, 2028
Loading map...